Compare OIG & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OIG | STTK |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.7M | 652.4M |
| IPO Year | 2026 | 2020 |
| Metric | OIG | STTK |
|---|---|---|
| Price | $9.05 | $6.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $15.40 |
| AVG Volume (30 Days) | 665.0K | ★ 1.5M |
| Earning Date | 11-22-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.78 | $1.70 |
| 52 Week High | $12.06 | $8.33 |
| Indicator | OIG | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 32.93 | 43.83 |
| Support Level | $7.78 | $5.85 |
| Resistance Level | $10.55 | $7.83 |
| Average True Range (ATR) | 0.87 | 0.47 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 45.21 | 33.24 |
Orion180 Insurance Group Inc operating as an insurance holding company. It is a founder-led, technology-focused, high-growth, high-margin specialty insurance group delivering insurance solutions with a growing footprint across the United States. The group operates in two segments: Services and Underwriting. The Services segment includes technology-enabled policy servicing operations, including intercompany revenue earned through service arrangements between the Services and Underwriting segments. The Underwriting segment includes a conventional, regulated insurance model focused on risk selection, pricing, and statutory capital management. The segment also includes a segregated cell designed to assume reinsurance risk.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.